2022 SABCS Highlights

CME

Highlights From the 2022 San Antonio Breast Cancer Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 17, 2023

Expiration: March 16, 2024

Sara A. Hurvitz
Sara A. Hurvitz, MD
Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1
Course Completed
References

  1. Johnston S, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS1-09. 
  2. Johnston SRD, Toi M, O’Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77-90. 
  3. Loibl S, Marmé F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer–the Penelope-B trial. J Clin Oncol. 2021;39:1518-1530. 
  4. Bardia A, Hurvitz S, Press MF, et al. TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS2-03.
  5. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New Engl J Med. 2022;387:9-20.
  6. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151-1161. 
  7. Tarantino P, Jin Q, Tayob N, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2021;8:1177-1183. 
  8. Montagna G, Mrdutt M, Botty A, et al. Oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemotherapy: the OPBC-04/EUBREAST-06/OMA study. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS4-02.
  9. Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072-1080. 
  10. Pagani O, Partridge A, Niman SM, et al. Pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer: primary results from the POSITIVE trial (IBCSG 48-14 / BIG 8-13). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS4-09. 
  11. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Eng J Med. 2014;371:107-118.
  12. Bardia A, Bidard F-C, Neven P, et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS3-01.
  13. Bidard F-C, Kaklamani, VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40:3246-3256. 
  14. Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21:250-260. 
  15. Elacestrant [prescribing information]. New York, NY: Stemline Therapeutics Inc.; 2023.
  16. Oliveira M, Pominchuck D, Nowecki Z, et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS3-02.
  17. Jhaveri K, Wang H-C, Ma C, et al. Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: results from the phase 1a/b EMBER study. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD13-12.
  18. Sledge Jr GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875-2884.
  19. Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrazole in metastatic breast cancer. N Eng J Med. 2019;380:1226-1234. 
  20. Bergh J, Jönsson P-E, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrazole in combination compared with anastrazole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30:1919-1925. 
  21. Lu Y-S, Mahidin EIBM, Azim H, et al. Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2- advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS1-10. 
  22. Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol. 2021;32:488-499.
  23. Park YH, Kim T-Y, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2019;20:1750-1759.
  24. Turner N, Oliveira M, Howell SJ, et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III CAPItello-291 trial. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS3-04.
  25. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929-1940. 
  26. Pierobon M, Ramos C, Wong S, et al. Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res. 2017;23:4919-4928. 
  27. Mayer EL, Ren Y, Wagle N, et al. Palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS3-06.
  28. Kalinsky K, Accordino MK, Chiuzan C, et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1004.
  29. Kalinsky K, Layman RM, Kaufman PA, et al. postMONARCH: a phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract TPS1117.
  30. Rugo H, Bardia A, Marmé F et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. Presented at the 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract LBA1001.
  31. Rugo H, Bardia A, Marmé F et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Presented at the 2022 European Society for Medical Oncology Congress; September 9-13, 2022. Abstract LBA76.
  32. Rugo H, Bardia A, Marmé F, et al. Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC): efficacy by Trop-2 expression in the TROPiCS-02 study of patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS1-11.
  33. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148-1156.
  34. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v.1.2023. nccn.org. Accessed February 6, 2023.
  35. Sacituzumab govitecan-hziy [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2023.
  36. Krop I, Park YH, Kim S-B, et al. Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS2-01. 
  37. Cortés J, Kim S, Chung W, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Presented at: 2021 European Society for Medical Oncology Congress; September 17-21, 2021. Abstract LBA1.
  38. Hurvitz S, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated survival results of the randomized, phase 3 study DESTINY-Breast03. Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract GS2-02.
  39. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022;401:105-117. 
  40. Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Eng J Med. 2022;386:1143-1154. 
  41. Freedman R, Ren S, Tayob N, et al. Translational Breast Cancer Research Consortium Trial 022: neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases (BCBM). Presented at: 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022. Abstract PD7-03.